Therapeutic area intelligence for Bone Metastases with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Eugia Pharma →

Assets

Eugia →

Recent signals(1)

RegulatoryJuly 19, 2026

Eugia Pharma submits supplemental application for Zoledronic Acid (ANDA209125)

Eugia Pharma has submitted a supplemental application for Zoledronic Acid under ANDA209125, currently under standard review.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.